DECIBEL THERAPEUTICS INC (DBTX)
US24343R1068 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, CPRI, CEQP, ESTE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, VRTV, CTG, DBTX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, CTG, DBTX, CPRI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, DBTX, TRHC
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, DBTX, VRTV, ZYNE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase...
Baird downgrades Decibel to neutral to reflect Regeneron takeover (NASDAQ:DBTX)
Baird has lowered its rating on Decibel Therapeutics (DBTX) to neutral following news that Regeneron (REGN) plans to buy the biotech for up to $213M in cash, including CVRs.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, DBTX, WMC, MITT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron
/PRNewswire/ -- Ademi LLP is investigating Decibel (NASDAQ: DBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Why Is Tango Therapeutics (TNGX) Stock Up 117% Today?
Tango Therapeutics (TNGX) stock is soaring higher on Wednesday after getting a couple of updates from analysts covering the shares.
YELL Stock Alert: Yellow Receives Nasdaq Delisting Notice
Yellow (YELL) stock is falling on Wednesday after the struggling U.S. trucking company received a Nasdaq delisting notice!
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN).
Decibel stock rises as Regeneron inks buyout deal
Regeneron (REGN) on Wednesday agreed to acquire Decibel Therapeutics (DBTX), a micro-cap biotech focused on gene therapies for $4.00 per share cash. Read more here.
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin...
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...